Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children
Open Access
- 1 August 2012
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (8) , 1071-1076
Abstract
To compare the long-term immunogenicity and seroprotection rates in healthy children following 23 years of vaccination with 10 μg or 20 μg doses of plasma-derived hepatitis B vaccine, we revisited all participants from our previous randomized controlled trial. At year 23, 81 participants were tested for HBV serological markers and HBV-DNA, and a booster dose was given to those with anti-HBs titer < 10 mIU/mL. After eliminating the interference of a Year 11 booster dose and vaccines received outside of the trial, around 50% of participants still maintained anti-HBs titers ≥ 10 mIU/mL in both 10 μg and 20 μg groups (p > 0.05). The peak immune response of vaccination (anti-HBs antibody levels at 12 mo after 1st vaccine dose) and Year 11 anti-HBs levels were significantly associated with Year 23 seroprotection rates. Most of the participants in both groups, regardless of their prior immune status, developed a rapid and robust anamnestic antibody response after the booster dose at year 23. No case of clinically significant HBV infection was observed during the entire study period of 23 y with only one transient HBsAg seroconversion in 10 μg vaccine group. We concluded that seroprotection provided by 10μg or 20 μg doses of hepatitis B vaccine persists for 23 years in more than half of vaccinated individuals in highly HBV-endemic areas, irrespective of 10 μg or 20 μg vaccine doses. Future studies with larger sample sizes comparing long-term efficacy of various doses of plasma-derived and recombinant HBV vaccines are recommended.Keywords
This publication has 23 references indexed in Scilit:
- Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: Results of a randomized placebo-controlled trial cohort from China where endemicity is highVaccine, 2011
- Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final reportVaccine, 2008
- The global impact of vaccination against hepatitis B: A historical overviewVaccine, 2008
- Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: A follow-up study at 15 years☆Vaccine, 2007
- EditorialJournal of Viral Hepatitis, 2007
- Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose scheduleVaccine, 2003
- Long‐Term Immunogenicity and Efficacy of Universal Hepatitis B Virus Vaccination in TaiwanThe Journal of Infectious Diseases, 2003
- Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicityVaccine, 1996
- Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescentsJournal of Adolescent Health, 1995
- Immunization of hospital personnel with low-dose intradermal hepatitis B vaccineVaccine, 1994